C2N Diagnostics

C2N Diagnostics applauds the Alzheimer's Association® and its workgroup for their revised criteria that uses a biological framework of disease, allowing researchers and healthcare providers to better identify Alzheimer’s disease at its different stages.  The updated criteria provide the foundation for the future development of effective treatment and prevention strategies, based on the latest scientific evidence and underlying mechanisms of disease biology. The new criteria also acknowledge the disruptive innovation in high-quality blood biomarkers (BBMs) to facilitate early detection in a more accessible, affordable, and equitable manner. We particularly appreciate the high bar the criteria set at 90% accuracy/CSF and amyloid PET equivalency for the right BBMs to be used for diagnosing amyloid pathology. C2N believes our PrecivityAD2™ test is ready to meet the expectation this criteria has set. The article, “Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease: Alzheimer’s Association Workgroup,” is available at https://lnkd.in/g3PT8HBf #liquidbiopsies #precisionmedicine #Alzheimersdisease #AlzheimersAssociation #brainhealth #bloodbiomarkers

C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology #liquidbiopsies #precisionmedicine #Alzheimersdisease #FDA #brainhealth #bloodbiomarkers #donanemab https://lnkd.in/eYNYKM5e

Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, shares his insights about C2N Diagnostics,LLC (“C2N”) entering into a non-exclusive agreement with Mayo Clinic Laboratories (MCL) for inclusion of C2N’s Precivity tests in MCL’s test offerings to its clients. “Increasing availability of C2N’s first-in-class and high performing blood test expands our arsenal of diagnostic tools, helping accelerate research while enabling early detection,” says Dr. Fillit.   The Precivity tests are innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a hallmark of Alzheimer's disease, and help inform medical management and treatment decisions. C2N acknowledges generous support from ADDF, National Institute on Aging (NIA), GHR Foundation, Alzheimer's Association® and BrightFocus Foundation. https://lnkd.in/egrT6TTT #liquidbiopsies #precisionmedicine #Alzheimersdisease #MayoClinicLaboratories #clinicallaboratoryservices #brainhealth

Did you see that C2N’s Precivity™ Tests are now also offered through Mayo Clinic Laboratories through a non-exclusive agreement? The Precivity tests are innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a hallmark of Alzheimer's disease, and help inform medical management and treatment decisions. Joel Braunstein, MD, C2N’s CEO, says, “While C2N Diagnostics continues expanding its own commercial, operational and IT infrastructure in the U.S. and strategic countries, we’re extremely pleased to work with Mayo Clinic Laboratories to broaden access to Precivity testing through Mayo Clinic Laboratories’ global distribution channels, extensive U.S. infrastructure and EMR connectivity. This non-exclusive partnership with Mayo Clinic Laboratories builds on our exclusive partnerships in other select markets. Overall, it demonstrates our commitment to excellence in clinical care and to collaborating with premium diagnostics leaders to make high-performance Alzheimer’s disease tests more accessible to healthcare providers and patients around the world. We look forward to elevating the quality of care for many patients in clinical need.” #liquidbiopsies #precisionmedicine #Alzheimersdisease #MayoClinicLaboratories #clinicallaboratoryservices #brainhealth https://lnkd.in/e_QVk5Es

C2N Diagnostics,LLC (“C2N”), which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement in select markets with Mayo Clinic Laboratories for inclusion of C2N’s Precivity™ tests in their test offerings. The Precivity tests are innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a hallmark of Alzheimer's disease, and help inform medical management and treatment decisions. We look forward to working with William G. Morice II, M.D., Ph.D., President & CEO and team at Mayo Clinic Laboratories. #liquidbiopsies #precisionmedicine #Alzheimersdisease #MayoClinicLaboratories #clinicallaboratoryservices #brainhealth https://lnkd.in/e_QVk5Es

National Institute on Aging (NIA) reports that a decade ago we knew of only 10 #genes associated with #Alzheimer’s disease. Today, we know of more than 70 relevant #genetic regions. Understanding the role genes play in Alzheimer’s and related dementias is key to finding effective methods of prevention and treatment. C2N acknowledges generous support from National Institute on Aging as well as GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation and Alzheimer's Association®. https://lnkd.in/gzZzNSAg

A retired journalist wrote a moving essay about his mom and her #AlzheimersDisease diagnosis. Now, he’s learned he has the same condition. Click here to read his inspiring essay: https://lnkd.in/dyZg4Quq #family #inspiringstory 

The Precivity™ tests are innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. This animated video provides a great overview for healthcare providers: https://lnkd.in/dsvG7EUz #AlzheimersDisease #patients #bloodtests #precisionmedicine

The Clinical Trial Vanguard recently reported on C2N Diagnostics' expansion into Japan through its Mediford Corporation partnership with Precivity™ blood testing for the Alzheimer’s disease and brain research market. C2N says the collaboration highlights the company’s growing global footprint for offering blood biomarker research testing that’s transforming clinical research and early diagnosis. https://lnkd.in/eTFGGg9J #Japan #Mediford #liquidbiopsy #Alzheimers

SciTechDaily reports on a study that explains how engineers at the UC San Diego say they’ve found that certain brain cells age faster than others. The researchers say these brain cells are more common in people with Alzheimer’s disease. They also noted differences in the aging of specific brain cells between sexes; the female cortex shows a greater proportion of “old” oligodendrocytes relative to “old” neurons compared to the male cortex. https://lnkd.in/e2_8pDmG #research #AlzheimersDisease #braincells #aging